Mindera Health and the National Psoriasis Foundation (NPF) are teamimg up to advance precision medicine in psoriasis.
Mindera Health’s Mind.Px uses gene expression analysis to help dermatologists determine the most effective biologic class for the treatment of individual psoriasis patients. By partnering with the NPF, Mindera Health aims to drive awareness of personalized medicine and accelerate the adoption of this technology.
Mind.Px uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91% positive predictive value,
“Our partnership with the National Psoriasis Foundation represents a pivotal moment in psoriasis care,” says Ron Rocca CEO of Mindera Health, in a news release. “Precision medicine is the future. Mindera Health is excited to be the first to bring precision medicine to psoriasis patients. We are aligned with the National Psoriasis Foundation’s goal to improve patient care and look forward to working with the NPF.”
For more information about Mindera Health and Mind.Px, visit www.MinderaHealth.com.
